金吾财讯 | 辉瑞(PFE)近日公布其结直肠癌靶向疗法重大突破，Braftovi（encorafenib）联合治疗方案在关键性III期BREAKWATER试验中展现出显著临床价值。数据显示，该组合疗法在晚期结直肠癌患者中实现61%的客观缓解率(ORR)，较传统化疗方案40%的应答率提升超50%，且具有统计学显著性差异（p<0.001）。在持续缓解时间指标上，Braftovi联合组中位缓解持续时间达到13.9个月，较化疗对照组11.1个月延长25%。尤为重要的是，该治疗方案安全性特征与各组分药物历史数据高度一致，未出现新的安全性信号，为其后续商业化奠定基础。此项突破性进展印证了BRAF抑制剂联合疗法的科学价值。Braftovi作为选择性BRAF激酶抑制剂，通过阻断MAPK信号通路关键节点，与抗EGFR单抗形成协同作用机制。该疗法特别针对BRAF V600E突变型转移性结直肠癌患者群体，这类约占结直肠癌患者10%-15%的难治性亚型，此前长期面临治疗方案有限、预后较差的临床困境。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.